{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-095167","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2025-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.152706+00:00","generated_at":"2026-05-18T06:54:48.508263+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Karyopharm cuts workforce 20%, explores strategic alternatives including sale","bullets":["Reducing workforce by ~20% as part of ongoing expense management; one-time costs immaterial.","Board evaluating financing, merger/sale, restructuring, or debt refinancing; no deal yet.","Engaged with potential investors under confidentiality; discussions did not result in a transaction.","Committed to Phase 3 trials in myelofibrosis and endometrial cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-095167","json":"https://secwatch.observer/filing/0000950170-25-095167.json","markdown":"https://secwatch.observer/filing/0000950170-25-095167.md","text":"https://secwatch.observer/filing/0000950170-25-095167.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000095017025095167/0000950170-25-095167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000095017025095167/kpti-20250711.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:54:48.508263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}